The Patent Finder

Lay Line Genomics S.P.A.

Also on record
Records under this name other than patents Lay Line Genomics S.P.A. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 10 of 10 · Back to Lay Line Genomics S.P.A.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,715,666Method for the potentiation of opioid analgesics effects on pain
Lapsed on the fee record
Ended May 6, 2026 · USPTO record
Lapsed on the fee recordEnded May 6, 2026USPTO record
US 8,691,221Analgesic treatment with prolonged effect
Lapsed on the fee record
Ended Apr 8, 2026 · USPTO record
Lapsed on the fee recordEnded Apr 8, 2026USPTO record
US 9,751,947Antibodies and derivatives thereof
Lapsed on the fee record
Ended Sep 5, 2025 · USPTO record
Lapsed on the fee recordEnded Sep 5, 2025USPTO record
US 7,988,966Method for the potentiation of opioid analgesics effects on pain
Lapsed on the fee record
Ended Aug 2, 2023 · USPTO record
Lapsed on the fee recordEnded Aug 2, 2023USPTO record
US 8,257,710Method for the treatment of pain with humanized anti-nerve growth factor antibodies
Formerly held
Lapsed on the fee record
Ended Sep 4, 2020 · USPTO record
Lapsed on the fee recordEnded Sep 4, 2020USPTO record
US 8,246,956Humanized anti-nerve growth factor antibodies
Formerly held
Lapsed on the fee record
Ended Aug 21, 2020 · USPTO record
Lapsed on the fee recordEnded Aug 21, 2020USPTO record
US 8,486,401Monoclonal antibodies binding to TrkA and acting as NGF-antagonist molecules and their use for treating pain induced by NGF
Term ended
Term ended Jul 22, 2020 · USPTO record
Term endedTerm ended Jul 22, 2020USPTO record
US 7,601,352Monoclonal antibodies and antigen binding fragments thereof capable of binding TrkA and inhibiting the functional activation of TrkA
Term ended
Term ended May 26, 2020 · USPTO record
Term endedTerm ended May 26, 2020USPTO record
US 8,877,491Polynucleotides encoding humanized anti-NGF antibodies
Formerly held
Lapsed on the fee record
Ended Nov 4, 2018 · USPTO record
Lapsed on the fee recordEnded Nov 4, 2018USPTO record
US 7,589,2192,5-bis-diamine-[1,4]benzoquinonic derivatives, useful for the treatment of alzheimer's disease, method for preparing them and intermediates of said method
Lapsed on the fee record
Ended Sep 15, 2013 · USPTO record
Lapsed on the fee recordEnded Sep 15, 2013USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited